Haemonetics Gets FDA Clearance For Enhancements to NexSys PCS System
By Will Feuer
Medical-technology company Haemonetics said it has received clearance from the Food and Drug Administration for enhancements to its NexSys PCS plasma-collection system.
The enhancements include a new plasma collection bowl and technology engineered to reduce procedure time, which the company expects to average between 33 minutes and 38 minutes.
The company said it is planning an initial market release of the system with its enhancements in the coming months.
The plasma business is Haemonetics' largest in terms of revenue, posting $131.2 million in the fourth quarter, up about 30% from a year ago.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
June 22, 2023 06:52 ET (10:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Apple Earnings: iPhone Growth Forecasts Drive Change in Fair Value
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted